Behind the production and discovery of today’s most advanced medicines is an often-overlooked challenge: purification — the highly specialized process of isolating and preparing compounds so they can be safely developed, manufactured, and analyzed. In this episode of Here’s the Deal, learn why KKR invested in Biotage, a company whose technologies help address this critical challenge across the global life sciences ecosystem.
KKR’s investment came during a period of market volatility, when weakness across the life sciences sector created an opportunity to acquire what we believe is a high-quality business at an attractive entry point. More importantly, we see a meaningful opportunity for strategic and operational value creation under our ownership.
While Biotage may operate behind the scenes, its technologies sit at the heart of some of health care’s most critical workflows, underscoring why KKR believes the company can become an even more important force in the future of life sciences.